C. diff Risk


Oral Bioavailability


Approximate Cost


Spectrum Of Activity


No dosage adjustment necessary in renal insufficiency, however inactive metabolites may accumulate in renal insufficiency.

Less than or equal to 12 years 10 mg/kg/dose IV/PO q8h
Maximum: 600 mg/dose

Greater than 12 years10 mg/kg/dose IV/PO q12h
Maximum: 600 mg/dose

General Information

Common Usage

  • Targeted or empiric therapy for gram positive infections including skin and soft tissue, and pneumonia.

  • Covers MRSA and VRE

Drug Monitoring

  • CBC at least once/week.

  • Visual testing for therapy greater than 3 months or if symptoms develop on therapy.

Adverse Effects

  • Myelosuppression (usually with >2weeks therapy)- reversible

  • Peripheral/optic neuropathy with prolonged courses

  • Rash

  • Elevated liver enzymes

  • Lactic acidosis

Major Interactions

  • SSRI and other serotonergics/MAOIs- increased risk of serotonin syndrome

  • Rifampin decreases linezolid levels.


Antimicrobial class: Oxazolidinone

Average serum half life:

  • Preterm neonates <1 week: 5.6 hours

  • Full-term neonates < 1 week : 3 hours

  • Full-term neonates ≥1 week to ≤ 28 days: 1.5 hours

  • Infants > 28 days to < 3 months: 1.8 hours

  • Infants and Children 3 months to 11 years: 2.9 hours

  • Adolescents: 4.1 hours

  • Adults: 4.9 hours

Route of Elimination:

  • Urine (~30% of total dose as parent drug, ~50 of total dose as inactive metabolites), two metabolites may accumulate in patients with severe renal impairment

  • Feces (9% of total dose as metabolites)